News

In the News part you can find Company Announcements, press releases and Online news as downloadable PDF files in English and Danish.

Company Announcements

RSS feed - Stock Exchange Announcements

Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities (25 July 2014)

Increased operating profit in local currencies by 15% in the first quarter of 2014 (1 May 2014)

Novo Nordisk increased operating profit in local currencies by 15% in 2013 (30 January 2014)

Novo Nordisk Increased operating profit by 10% in the first nine months of 2013 (31 October 2013)

Novo Nordisk increased operating profit by 15% in the first six months of 2013 (8 August 2013)

Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes (31 May 2013)

Increased operating profit by 18% in the first quarter of 2013 (1 May 2013)

Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 February 2013)

Novo Nordisk increased operating profit by 32% in 2012 (31 January 2013)

Tresiba® and Ryzodeg® receive marketing authorisations in Europe (21 January 2013)

Ryzodeg® (insulin degludec/insulin aspart) approved in Japan (25 December 2012)

The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 December 2012)

Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan (3 December 2012)

Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee (9 November 2012)

FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart (6 November 2012)

Novo Nordisk increased operating profit by 34% in the first nine months of 2012 (31 October 2012)

FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart (25 October 2012)

Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities (19 October 2012)

Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba® (19 October 2012)

Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan (28 September 2012)

Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan (31 August 2012)

Novo Nordisk increased operating profit by 31% in the first half of 2012 (9 August 2012)

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart (18 July 2012)

Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months (8 June 2012)

Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012 (27 April 2012)

Novo Nordisk increased operating profit by 18% in 2011 (2 February 2012)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan (22 December 2011)

Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes (7 November 2011)

Novo Nordisk A/S: Interim financial report for the period 1 January 2011 to 30 September 2011 (27 October 2011)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US (29 September 2011)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe (26 September 2011)

Novo Nordisk increased operating profit by 24% in the first quarter of 2011 (28 April 2011)

Novo Nordisk increased operating profit by 27% in 2010 (2 February 2011)

Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies (22 December 2010)

Interim financial report for the period 1 January 2010 to 30 September 2010 (28 October 2010)

Interim financial report for the period 1 January 2010 to 30 June 2010 (5 August 2010)

Novo Nordisk re-initiates phase 3 development of liraglutide for obesity (22 June 2010)

Interim financial report for the period 1 January 2010 to 31 March 2010 (27 April 2010)

Financial statement for the period 1 January 2008 to 30 September 2008 (30 October 2008)

Novo Nordisk provides update on corporate strategy at its Capital Markets Day (26 September 2008)

Press Releases

RSS feed - Press Releases

New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes (14 June 2014)

Novo Nordisk to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA (10 June 2014)

Tresiba® and Victoza® receive positive opinions from CHMP for label updates expanding indications for use in adults with type 2 diabetes (21 March 2014)

Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation (10 December 2013)

Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes1 (3 December 2013)

IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin* (3 December 2013)

IDegLira improves glycaemic control throughout the day with no weight gain and a low rate of hypoglycaemia* (27 September 2013)

New study demonstrates efficacy throughout 2.5 years for Tresiba® (24 September 2013)

Study confirms improved health-related quality of life for patients with type 2 diabetes receiving Tresiba® (22 June 2013)

Novo Nordisk lancerer Tresiba® (insulin degludec) i Danmark (4 March 2013)

Tresiba® now ready to be launched in Japan (13 February 2013)

Novo Nordisk upgraded to ‘A1’ by Moody’s (5 December 2012)

Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia than insulin glargine in a 2-year study investigating 1,030 people with type 2 diabetes who had not previously used insulin (2 October 2012)

Investigational ultra-long-acting insulin degludec reduces rates of nocturnal hypoglycaemia in type 2 diabetes patients versus insulin glargine (9 June 2012)

Data show that the combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in type 1 and type 2 diabetes patients (6 December 2011)

Data show that ultra-long-acting insulin degludec can be flexibly dosed at any time of the day in people with type 2 diabetes (14 September 2011)

Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control in patients with type 1 and type 2 diabetes (27 June 2011)

Phase 2 data for ultra-long-acting insulin degludec show the potential to effectively lower blood sugar, including when used three times a week (26 June 2010)

Featured stories

RSS feed - Featured stories

No results matching your criteria

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •